ClinicalTrials.gg
RecruitingNCT06494904ED-ENVISIONUpdated May 28, 2026

Standard Versus High Dose ED-Initiated Buprenorphine Induction

A Phase 3 interventional study of Buprenorphine in Opioid Use Disorder, sponsored by Yale University. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Yale University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies testing buprenorphine in Opioid-Related Disorders — 19 open to participants now, 21 under way, 5 of them phase 3. Buprenorphine · Opioid-Related Disorders.

Planned enrollment
15th of 172
360 · median 19
Started
2024
with 3 others
Phase 3
37 of 173
2 open now
Primary completion
2027-09
later than 12 of 20 live
Registered
163rd of 173
by date
Lead sponsor
12 of 173
Yale University

Among the 173 studies testing buprenorphine in Opioid-Related Disorders, this one is the 15th largest by planned enrollment of the 172 interventional ones that give a count, is one of 4 that started in 2024, is one of 37 in phase 3, reaches primary completion later than 12 of the 20 other live ones, and was the 163rd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

19 of the 173 studies testing buprenorphine in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies testing buprenorphine in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.

Read the detailed description

This study will recruit, train, and provide resources to approximately 4 ED systems throughout the U.S. to recruit ED patients presenting with OUD not receiving medications for opioid use disorder (MOUD) as part of an RCT to compare SDI (Zubsolv 5.7/1.4 mg buprenorphine/naloxone* plus 2 placebo tablets) with HDI (three Zubsolv 5.7/1.4 mg* buprenorphine/naloxone tablets) to evaluate rate of participation in OUD treatment within 10 days post-randomization and differences in outcomes of tolerability, opioid withdrawal symptoms, craving, and use of illicit drugs.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Buprenorphine
  • Substance use disorder treatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients enrolled into the study must:

  1. Be 18-65 years of age.
  2. Be treated in the ED during study screening hours.
  3. Meet diagnostic criteria for moderate to severe OUD.
  4. Have a Clinical Opiate Withdrawal Scale (COWS) score of ≥8 at enrollment (including 2 objective signs of withdrawal at enrollment).
  5. Have a urine toxicology test that is positive for opioids.
  6. Be able to speak English sufficiently to understand the study procedures and provide written to participate in the study.

Exclusion criteria

Exclusion Criteria:

All patients enrolled into the study must not:

  1. Have a medical or psychiatric condition that requires hospitalization at the time of index ED visit.
  2. Have a known reaction to buprenorphine/naloxone
  3. Be actively suicidal or severely cognitively impaired precluding .
  4. Require ongoing prescription for opioid analgesics.
  5. Have a physical exam or reported history consistent with severe liver failure
  6. Have a positive urine test for methadone and reported use in the past 72 hours
  7. Be a prisoner or in police custody at the time of index ED visit.
  8. Be unwilling to follow study procedures (e.g., unwilling to provide permission to contact referral provider/program or unavailable for the follow-up assessments)
  9. Have prior enrollment in the current study.
  10. Receiving MOUD treatment within the past 7 days.
  11. Be pregnant as determined by human gonadotropin (hCG) testing at the index ED visit
  12. Have a respiratory rate \<8 or oxygen saturation \<93%
  13. Be a participant in any other clinical trial in which medications are being delivered or the use of an drug or device within the last 30 days
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    High Dose SL-BUP

    Participants will receive three 5.7 mg Zubsolv pills; all will be active medication.

    Drug: Buprenorphine

  • Active comparator
    Standard SL-BUP

    Participants will receive three pills; one 5.7 mg Zubsolv pill with active medication and two placebo pills.

    Drug: Buprenorphine

Interventions

  • All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.

    Also known as: Zubsolv

06

What researchers measure

Primary outcomes

  1. Engagement in Treatment (10)

    The proportion of patients in each of the two study arms participating in OUD treatment within 10 days after the study randomization

    Time frame: Within 10 days after study randomization

Secondary outcomes

  1. Craving

    The maximum intensity of opioid cravings during the preceding 24 hours assessed daily for 10 days post randomization using a numerical rating scale (0 to 10).

    Time frame: Measured daily for 10 days post randomization

  2. Withdrawal

    The maximum intensity of opioid withdrawal symptoms during the preceding 24 hours assessed daily for 10 days post randomization using a numerical rating scale (0 to 10).

    Time frame: Measured daily for 10 days post randomization

  3. Substance Use

    The number of days with illicit opioid and other substance use based on self-reported data obtained daily during the first 10 days post randomization

    Time frame: Measured daily for 10 days post randomization

  4. Engagement in Treatment (30)

    The proportion of patients in each of the two study arms participating in OUD treatment

    Time frame: Within 30 days after randomization

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Hawk K, Herring A, Chawarski M, Anderson ES, Baumann M, Dorey A, Holtyn AF, Jones C, Martel S, Owens P, Kmiecik K, Strout TD, Taillac P, Lofwall M, Walsh SL, D'Onofrio G. Emergency Department-initiated standard versus high-dose buprenorphine induction (ENVISION): a randomised clinical trial protocol. BMJ Open. 2026 Jun 3;16(6):e113762. doi: 10.1136/bmjopen-2025-113762. PubMed 42236100 ↗

Individual participant data

Plan to share: Yes — In line with the National Institutes of Health Helping to End Addiction Long-term (NIH HEAL) Initiative Public Access and Data Sharing Policy, publications and underlying primary data will be made available to the public.

Time frame: Data will be made available after 1) the primary paper has been accepted for publication, or 2) the data is locked for more than 18 months, whichever comes first.

Access criteria: De-identified scientific data generated from this study will be available to the public in the NIDA data repository, per NIDA CTN policy and the Data Management and Sharing Plan for this study.

Data sharing details ↗ · datashare.nida.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 33 months after the start.

Of 31 phase 3 interventional studies under Opioid-Related Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Dec 6, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2028
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06494904
Lead sponsor
Yale University
Collaborators
National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, National Institute on Drug Abuse (NIDA), Alameda Health System
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Dec 6, 2024
Primary completion
Sep 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 28, 2026

Study contacts

Gail D'Onofrio, MD, MS
Contact
gail.donofrio@yale.edu
2037857059
Kathryn Hawk, MD, MHS
Contact
kathryn.hawk@yale.edu
2037857899
Gail D'Onofrio, MD, MS
principal investigator · Yale University
Kathryn Hawk
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion